Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of SR121463B in SIADH
2004-005239-25Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of satavaptan in syndrome of inappropriate antidiuresis (SIAD), sponsored by Sanofi. Primary endpoint: Serum sodium. Started May 2005; status: completed.
02
Drugs
satavaptan
03
Conditions
syndrome of inappropriate antidiuresis (SIAD)
Beyond the preview
Go deeper on 2004-005239-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005239-25.